BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14(1): 1-14 [PMID: 18176955 DOI: 10.3748/wjg.14.1]
URL: https://www.wjgnet.com/1007-9327/full/v14/i1/1.htm
Number Citing Articles
1
Takahito Yagi. Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 2008; 120(1): 63 doi: 10.4044/joma.120.63
2
Masatoshi Kudo. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practiceInternational Journal of Clinical Oncology 2010; 15(3): 242 doi: 10.1007/s10147-010-0089-y
3
Christèle Desbois-Mouthon, Aurore Baron, Marie-José Blivet-Van Eggelpoël, Laetitia Fartoux, Corinne Venot, Friedhelm Bladt, Chantal Housset, Olivier Rosmorduc. Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular CarcinomaClinical Cancer Research 2009; 15(17): 5445 doi: 10.1158/1078-0432.CCR-08-2980
4
C. Berasain, J. Castillo, M.J. Perugorria, M.U. Latasa, J. Prieto, M.A. Avila. Inflammation and Liver CancerAnnals of the New York Academy of Sciences 2009; 1155(1): 206 doi: 10.1111/j.1749-6632.2009.03704.x
5
B Nitzsche, C Gloesenkamp, M Schrader, M Ocker, R Preissner, M Lein, A Zakrzewicz, B Hoffmann, M Höpfner. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumoursBritish Journal of Cancer 2010; 103(1): 18 doi: 10.1038/sj.bjc.6605725
6
Rebecca Allen, Daneng Li. Oncology in the Precision Medicine Era2020; : 259 doi: 10.1007/978-3-030-31471-2_16
7
Chareeporn Akekawatchai, Marina Kochetkova, Jane Holland, Shaun R McColl. Chemokine Receptors in Cancer2009; : 1 doi: 10.1007/978-1-60327-267-4_1
8
Shinji Tanaka, Shigeki Arii. Molecularly targeted therapy for hepatocellular carcinomaKanzo 2008; 49(4): 133 doi: 10.2957/kanzo.49.133
9
Li Chen, Yan Shi, Cheng-ying Jiang, Li-xin Wei, Ya-li Lv, Yu-lan Wang, Guang-hai Dai. Coexpression of PDGFR-Alpha, PDGFR-Beta and VEGF as a Prognostic Factor in Patients with Hepatocellular CarcinomaThe International Journal of Biological Markers 2011; 26(2): 108 doi: 10.5301/JBM.2011.8322
10
Silvia Ribback, Verena Sailer, Enrico Böhning, Julia Günther, Jaqueline Merz, Frauke Steinmüller, Kirsten Utpatel, Antonio Cigliano, Kristin Peters, Maria Pilo, Matthias Evert, Diego Calvisi, Frank Dombrowski. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat ModelsInternational Journal of Molecular Sciences 2016; 17(10): 1618 doi: 10.3390/ijms17101618
11
María J. Cuevas, Juliana Tieppo, Norma Possa Marroni, María J. Tuñón, Javier González-Gallego. Suppression of Amphiregulin/Epidermal Growth Factor Receptor Signals Contributes to the Protective Effects of Quercetin in Cirrhotic RatsThe Journal of Nutrition 2011; 141(7): 1299 doi: 10.3945/jn.111.140954
12
Thorsten Maass, Florian R. Thieringer, Amrit Mann, Thomas Longerich, Peter Schirmacher, Dennis Strand, Torsten Hansen, Peter R. Galle, Andreas Teufel, Stephan Kanzler. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesisInternational Journal of Cancer 2011; 128(6): 1259 doi: 10.1002/ijc.25469
13
Sania Safdar Butt, Khushbukhat Khan, Yasmin Badshah, Mehak Rafiq, Maria Shabbir. Evaluation of pro-apoptotic potential of taxifolin against liver cancerPeerJ 2021; 9: e11276 doi: 10.7717/peerj.11276
14
Yue Ma, Ying-Chun Xu, Lei Tang, Zan Zhang, Jian Wang, Hong-Xia Wang. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safetyExperimental Hematology & Oncology 2012; 1(1) doi: 10.1186/2162-3619-1-11
15
D. Koeberle, P. Samaras. Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomasmemo - Magazine of European Medical Oncology 2011; 4(2): 94 doi: 10.1007/s12254-011-0260-9
16
Carmen Berasain, Maria J. Perugorria, Maria Ujue Latasa, Josefa Castillo, Saioa Goñi, Mónica Santamaría, Jesús Prieto, Matías A. Avila. The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver CancerExperimental Biology and Medicine 2009; 234(7): 713 doi: 10.3181/0901-MR-12
17
Amanda Psyrri, Nikolaos Arkadopoulos, Maria Vassilakopoulou, Vassilios Smyrniotis, George Dimitriadis. Pathways and targets in hepatocellular carcinomaExpert Review of Anticancer Therapy 2012; 12(10): 1347 doi: 10.1586/era.12.113
18
Haiyu Li, Zhenggang Ren, Xiaonan Kang, Lan Zhang, Xuefei Li, Yan Wang, Tongchun Xue, Yuefang Shen, Yinkun Liu. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cellsBMC Cancer 2009; 9(1) doi: 10.1186/1471-2407-9-366
19
Vladimir Beljanski, Clayton S. Lewis, Charles D. Smith. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenograftsCancer Biology & Therapy 2011; 11(5): 524 doi: 10.4161/cbt.11.5.14677
20
Jürgen S. Scheele, Jan Harder, Zoran Stankovic, Daniel Räpple, Annette Dorn, Hans C. Spangenberg, Hubert E. Blum. Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case reportJournal of Medical Case Reports 2011; 5(1) doi: 10.1186/1752-1947-5-478
21
Ji-Hua Shi, Shu-Zheng Liu, Lene Wierød, Hanne Scholz, Jarl Andreas Anmarkrud, Henrik S. Huitfeldt, Shui-Jun Zhang, Pål-Dag Line. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liverJournal of Surgical Oncology 2013; 107(4): 393 doi: 10.1002/jso.23224
22
Maureen P. Kohi, Nicholas Fidelman, David M. Naeger, Jeanne M. LaBerge, Roy L. Gordon, Robert K. Kerlan. Hepatotoxicity after Transarterial Chemoembolization and Transjugular Intrahepatic Portosystemic Shunt: Do Two Rights Make a Wrong?Journal of Vascular and Interventional Radiology 2013; 24(1): 68 doi: 10.1016/j.jvir.2012.08.032
23
Brian I. Carr, Susan Kralian. Hepatocellular Carcinoma2009; : 589 doi: 10.1007/978-1-60327-376-3_22
24
Xiaofeng Li, Dong Dai, Xiuyu Song, Jianjing Liu, Lei Zhu, Wengui Xu. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinomaClinics and Research in Hepatology and Gastroenterology 2014; 38(5): 583 doi: 10.1016/j.clinre.2014.04.010
25
Quirino Lai, Alessandro Vitale, Tommaso Manzia, Francesco Foschi, Giovanni Levi Sandri, Martina Gambato, Fabio Melandro, Francesco Russo, Luca Miele, Luca Viganò, Patrizia Burra, Edoardo Giannini. Platelets and Hepatocellular Cancer: Bridging the Bench to the ClinicsCancers 2019; 11(10): 1568 doi: 10.3390/cancers11101568
26
Chiao-Fang Teng, Han-Chieh Wu, Woei-Cherng Shyu, Long-Bin Jeng, Ih-Jen Su. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular CarcinomaCell Transplantation 2017; 26(3): 429 doi: 10.3727/096368916X694382
27
Thi Bich Uyen Le, Thanh Chung Vu, Rebecca Zhi Wen Ho, Aldo Prawira, Lingzhi Wang, Boon Cher Goh, Hung Huynh. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular CarcinomaInternational Journal of Molecular Sciences 2020; 21(24): 9405 doi: 10.3390/ijms21249405
28
Xuan Wang, Jieyu Ding, Yuanyuan Feng, Lingling Weng, Guangqiang Zhao, Jianfeng Xiang, Minguang Zhang, Dongwei Xing. Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharidesOncology Letters 2017; 13(3): 1509 doi: 10.3892/ol.2017.5602
29
Yunsheng Zhao, Qin Gao, Liu Pei, Chunhua Wang, Liang Jin, Fei Liao. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular CarcinomaThe International Journal of Biological Markers 2017; 32(4): 361 doi: 10.5301/ijbm.5000299
30
Andrea N. Chisari, Patricia Sancho, Laia Caja, Esther Bertran, Isabel Fabregat. Lack of amino acids in mouse hepatocytes in culture induces the selection of preneoplastic cellsCellular Signalling 2012; 24(1): 325 doi: 10.1016/j.cellsig.2011.09.018
31
Ziqiang Li, Mei Tang, Bo Ling, Shiying Liu, Yu Zheng, Chunlai Nie, Zhu Yuan, Liangxue Zhou, Gang Guo, Aiping Tong, Yuquan Wei. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinomaJournal of Molecular Medicine 2014; 92(3): 291 doi: 10.1007/s00109-013-1104-3
32
Dieter Koeberle, Michael Montemurro, Panagiotis Samaras, Pietro Majno, Mathew Simcock, Andreas Limacher, Stefanie Lerch, Katalin Kovàcs, Roman Inauen, Vivianne Hess, Piercarlo Saletti, Markus Borner, Arnaud Roth, György Bodoky. Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)The Oncologist 2010; 15(3): 285 doi: 10.1634/theoncologist.2009-0316
33
Takao Watanabe, Hiroko Ninomiya, Takashi Saitou, Sota Takanezawa, Shin Yamamoto, Yusuke Imai, Osamu Yoshida, Ryosuke Kawakami, Masashi Hirooka, Masanori Abe, Takeshi Imamura, Yoichi Hiasa. Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivoScientific Reports 2020; 10(1) doi: 10.1038/s41598-020-61579-x
34
Mónica Enguita-Germán, Puri Fortes. Targeting the insulin-like growth factor pathway in hepatocellular carcinomaWorld Journal of Hepatology 2014; 6(10): 716-737 doi: 10.4254/wjh.v6.i10.716
35
Melanie B. Thomas, Elizabeth Garrett-Mayer, Munazza Anis, Kate Anderton, Tricia Bentz, Andie Edwards, Alan Brisendine, Geoffrey Weiss, Abby B. Siegel, Johanna Bendell, Ari Baron, Vinay Duddalwar, Anthony El-Khoueiry. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular CarcinomaOncology 2018; 94(6): 329 doi: 10.1159/000485384
36
Jian Zhu, Yanping Wang, Yunhui Yu, Zheng Wang, Tingting Zhu, Xiukun Xu, Haiyan Liu, David Hawke, Dapeng Zhou, Yunsen Li. Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissuesLiver International 2014; 34(1): 147 doi: 10.1111/liv.12265
37
Marcus Alexander Wörns, Peter Robert Galle. Novel inhibitors in development for hepatocellular carcinomaExpert Opinion on Investigational Drugs 2010; 19(5): 615 doi: 10.1517/13543781003767418
38
Johannes Lammer, Katarina Malagari, Thomas Vogl, Frank Pilleul, Alban Denys, Anthony Watkinson, Michael Pitton, Geraldine Sergent, Thomas Pfammatter, Sylvain Terraz, Yves Benhamou, Yves Avajon, Thomas Gruenberger, Maria Pomoni, Herbert Langenberger, Marcus Schuchmann, Jerome Dumortier, Christian Mueller, Patrick Chevallier, Riccardo Lencioni. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology 2010; 33(1): 41 doi: 10.1007/s00270-009-9711-7
39
Munawar Abbas, Farhan Saeed, Faqir Muhammad Anjum, Muhammad Afzaal, Tabussam Tufail, Muhammad Shakeel Bashir, Adnan Ishtiaq, Shahzad Hussain, Hafiz Ansar Rasul Suleria. Natural polyphenols: An overviewInternational Journal of Food Properties 2017; 20(8): 1689 doi: 10.1080/10942912.2016.1220393
40
A C Hoover, G L Strand, P N Nowicki, M E Anderson, P D Vermeer, A J Klingelhutz, A D Bossler, J V Pottala, WJAJ Hendriks, J H Lee. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathwayOncogene 2009; 28(45): 3960 doi: 10.1038/onc.2009.251
41
Andrew Scanga, Kris Kowdley, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?Hepatology 2009; 49(1): 332 doi: 10.1002/hep.22756
42
Meng Zhao, Hong-wei He, Huan-xing Sun, Kai-huan Ren, Rong-guang Shao. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cellsBiochemical and Biophysical Research Communications 2009; 387(2): 239 doi: 10.1016/j.bbrc.2009.06.128
43
Ronald Koschny, Carsten Grüllich, Tom Michael Ganten. Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären KarzinomsOnkopipeline 2008; 1(3): 109 doi: 10.1007/s15035-008-0136-6
44
Hung Huynh. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinomaCancer 2010; 116(5): 1315 doi: 10.1002/cncr.24863
45
Eyal Mishani, Aviv Hagooly. Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in CancerJournal of Nuclear Medicine 2009; 50(8): 1199 doi: 10.2967/jnumed.109.062117
46
Axel R. Pries, Annemiek J. M. Cornelissen, Anoek A. Sloot, Marlene Hinkeldey, Matthew R. Dreher, Michael Höpfner, Mark W. Dewhirst, Timothy W. Secomb, Jason A. Papin. Structural Adaptation and Heterogeneity of Normal and Tumor Microvascular NetworksPLoS Computational Biology 2009; 5(5): e1000394 doi: 10.1371/journal.pcbi.1000394
47
Masatoshi Kudo. Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular CarcinomaDigestive Diseases 2011; 29(3): 289 doi: 10.1159/000327562
48
Jacek Wilczynski, Markus Duechler, Malgorzata Czyz. Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part IArchivum Immunologiae et Therapiae Experimentalis 2011; 59(4): 289 doi: 10.1007/s00005-011-0131-4
49
Clarinda W. L. Chua, Su Pin Choo. Targeted Therapy in Hepatocellular CarcinomaInternational Journal of Hepatology 2011; 2011: 1 doi: 10.4061/2011/348297
50
Chaodong Li, Mei Ge, Yu Yin, Minyu Luo, Daijie Chen. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cellsMolecular and Cellular Biochemistry 2012; 370(1-2): 127 doi: 10.1007/s11010-012-1404-x
51
Yoshiaki Mizuguchi, Toshihiro Takizawa, Eiji Uchida. Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replicationWorld Journal of Hepatology 2015; 7(4): 696-702 doi: 10.4254/wjh.v7.i4.696
52
Ji-Hua Shi, Henrik S. Huitfeldt, Zhen-He Suo, Pål-Dag Line. Growth of hepatocellular carcinoma in the regenerating liverLiver Transplantation 2011; 17(7): 866 doi: 10.1002/lt.22325
53
Yoshiaki Mizuguchi, Toshihiro Takizawa, Hiroshi Yoshida, Eiji Uchida. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic reviewHepatology Research 2016; 46(5): 391 doi: 10.1111/hepr.12606
54
Thomas Yau, Pierre Chan, Richard Epstein, Ronnie T Poon. Evolution of systemic therapy of advanced hepatocellular carcinomaWorld Journal of Gastroenterology 2008; 14(42): 6437-6441 doi: 10.3748/wjg.14.6437
55
Wenjiao Zeng, Annette S.H. Gouw, Marius C. van den Heuvel, Peter J. Zwiers, Pieter E. Zondervan, Sibrand Poppema, Nong Zhang, Inge Platteel, Koert P. de Jong, Grietje Molema. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularizationHepatology 2008; 48(5): 1517 doi: 10.1002/hep.22490
56
Federico Aucejo, Richard Kim, Nizar Zein, Cristiano Quintini, Teresa Diago Uso, Rocio Lopez, Bijan Eghtesad, John Fung, Charles Miller, Lisa Yerian. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond milan criteriaLiver Transplantation 2009; 15(2): 169 doi: 10.1002/lt.21678
57
Maurizio Salvadori. Antineoplastic effects of mammalian target of rapamycine inhibitorsWorld Journal of Transplantation 2012; 2(5): 74-83 doi: 10.5500/wjt.v2.i5.74
58
Bernard E. Van Beers, Valérie Vilgrain. Biomarkers in abdominal imagingAbdominal Imaging 2009; 34(6): 663 doi: 10.1007/s00261-008-9480-9
59
Rachel Friedman Ohana, Robin Hurst, Mike Rosenblatt, Sergiy Levin, Thomas Machleidt, Thomas A. Kirkland, Lance P. Encell, Matthew B. Robers, Keith V. Wood. Utilizing a Simple Method for Stoichiometric Protein Labeling to Quantify Antibody BlockadeScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-43469-z
60
Hung Huynh. Molecularly targeted therapy in hepatocellular carcinomaBiochemical Pharmacology 2010; 80(5): 550 doi: 10.1016/j.bcp.2010.03.034
61
Kai Zhu, Zhi Dai, Jian Zhou. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapyBiomarker Research 2013; 1(1) doi: 10.1186/2050-7771-1-10
62
Laura Gramantieri, Francesca Fornari, Elisa Callegari, Silvia Sabbioni, Giovanni Lanza, Carlo M. Croce, Luigi Bolondi, Massimo Negrini. MicroRNA involvement in hepatocellular carcinomaJournal of Cellular and Molecular Medicine 2008; 12(6a): 2189 doi: 10.1111/j.1582-4934.2008.00533.x
63
David Vauzour, Ana Rodriguez-Mateos, Giulia Corona, Maria Jose Oruna-Concha, Jeremy P. E. Spencer. Polyphenols and Human Health: Prevention of Disease and Mechanisms of ActionNutrients 2010; 2(11): 1106 doi: 10.3390/nu2111106
64
Susan Kralian, Brian I. Carr. Hepatocellular Carcinoma2016; : 513 doi: 10.1007/978-3-319-34214-6_34
65
Makoto Meguro, Toru Mizuguchi, Masaki Kawamoto, Koichi Hirata. The Molecular Pathogenesis and Clinical Implications of Hepatocellular CarcinomaInternational Journal of Hepatology 2011; 2011: 1 doi: 10.4061/2011/818672
66
Melanie B. Thomas, Deborah Jaffe, Michael M. Choti, Jacques Belghiti, Steven Curley, Yuman Fong, Gregory Gores, Robert Kerlan, Phillipe Merle, Bert O'Neil, Ronnie Poon, Lawrence Schwartz, Joel Tepper, Francis Yao, Daniel Haller, Margaret Mooney, Alan Venook. Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning MeetingJournal of Clinical Oncology 2010; 28(25): 3994 doi: 10.1200/JCO.2010.28.7805
67
Lorenza Rimassa, Armando Santoro, Bruno Daniele, Domenico Germano, Antonio Gasbarrini, Stefania Salvagni, Gianluca Masi, Giovanni Abbadessa, Maria Lamar, Terri Goldberg, Camillo Porta. Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian CentersTumori Journal 2015; 101(2): 139 doi: 10.5301/tj.5000217
68
Shinji Tanaka, Shigeki Arii. Molecularly targeted therapy for hepatocellular carcinomaCancer Science 2009; 100(1): 1 doi: 10.1111/j.1349-7006.2008.01006.x
69
E. A. Kotelnikova, M. D. Logacheva, E. R. Nabieva, M. A. Pyatnitskiy, D. V. Vinogradov, A. S. Makarova, A. V. Demin, A. G. Paleeva, O. S. Kremenetskaya, A. A. Penin, A. V. Klepikova, A. S. Kasianov, D. A. Shavochkina, N. E. Kudashkin, Yu. I. Patyutko, N. S. Mugue, A. S. Kondrashov, N. L Lazarevich. NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case reportBiopolymers and Cell 2015; 31(6): 436 doi: 10.7124/bc.000901
70
Liliana Montella, Raffaele Addeo, Michele Caraglia, Salvatore Del Prete. Latest developments in targeted therapy for hepatocellular carcinomaExpert Review of Anticancer Therapy 2010; 10(10): 1635 doi: 10.1586/era.10.146
71
D. Germano, V. Tinessa, E. Barletta, L. Cannella, B. Daniele. Targeted Therapy for Advanced Hepatocellular Cancer in the Elderly: Focus on SorafenibDrugs & Aging 2013; 30(11): 887 doi: 10.1007/s40266-013-0124-6
72
Jin Zhang, Xiangdong Jiang, Yingnan Jiang, Mingrui Guo, Shouyue Zhang, Jingjing Li, Jun He, Jie Liu, Jinhui Wang, Liang Ouyang. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugsEuropean Journal of Medicinal Chemistry 2016; 108: 495 doi: 10.1016/j.ejmech.2015.12.016